Otelixizumab also known as TRX4 is a monoclonal antibody which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories.
This page contains content from the copyrighted Wikipedia article "Otelixizumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.